Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

NCT00820911 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: cyclosporine (reduced exposure) / everolimus
DRUG: AEB071 300 mg b.i.d. / everolimus
DRUG: AEB071 200 mg b.i.d. / everolimus

Sponsor

Novartis Pharmaceuticals